[Form 4] ReShape Lifesciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Robert Dickey IV, Chief Financial Officer and Director of Vyome Holdings, Inc., reported a change in beneficial ownership related to a merger involving Vyome Therapeutics. The reporting person received 762 shares of Vyome Holdings common stock on 08/15/2025 in exchange for 3,810,000 shares of Vyome Therapeutics common stock under the Merger Agreement, which converted every 5,000 Vyome Therapeutics shares into one share of the issuer. The Merger resulted in Vyome Therapeutics becoming a subsidiary of the issuer and the renamed parent company Vyome Holdings, Inc. The Form 4 discloses the acquisition as a non-derivative transaction and indicates the reporting person holds the shares directly.

Positive

• Transparency: Reporting person timely filed a Form 4 disclosing the merger-related acquisition, which supports regulatory transparency
• Clear conversion terms: The filing specifies the conversion ratio (1 Vyome Holdings share per 5,000 Vyome Therapeutics shares), clarifying the mechanics of the ownership change

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider received a small number of parent-company shares via a merger conversion that consolidated a large base of subsidiary shares.

The reported transaction is a mechanical conversion under a merger agreement, where a large block of subsidiary common stock (3,810,000 shares) converted into a comparatively small number of parent-company shares (762) at a fixed ratio (1-for-5,000). For investors, this does not reflect an open-market purchase or sale by the insider but the exchange mechanics of the corporate reorganization. The Form 4 shows ownership is direct and the transaction code indicates an acquisition by virtue of the merger. There is no cash consideration disclosed for the reporting person in the filing.

Corporate Governance Expert

TL;DR: The filing documents an internal restructuring transfer; it is procedural rather than an operational change.

This disclosure notifies shareholders of a change in beneficial ownership resulting from the completion of a merger and the subsequent stock conversion ratio. It confirms proper reporting by an insider who is an officer and director, supporting transparency. The filing does not disclose any related-party compensation, option exercises, or other governance actions beyond the conversion. Material governance implications would require additional information such as pro forma share counts, dilution impact, or changes to executive compensation, which are not included here.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dickey Robert IV

(Last) (First) (Middle)

HARVARD SQUARE,

ONE MIFFLIN PLACE, SUITE 400

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vyome Holdings, Inc [ HIND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		A(1)		762	A	(1)	762	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.

	/s/ Robert Dickey	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for Vyome Holdings (HIND) report?

It reported that Robert Dickey IV received 762 shares of Vyome Holdings common stock in exchange for 3,810,000 shares of Vyome Therapeutics common stock under the Merger Agreement.

Why did Robert Dickey IV receive only 762 shares after the merger?

The Merger Agreement converted Vyome Therapeutics shares into Vyome Holdings shares at a ratio of 1 share of Vyome Holdings for every 5,000 shares of Vyome Therapeutics, resulting in 762 shares from 3,810,000 prior shares.

What is the reporting person's role at the company?

The Form 4 identifies the reporting person as Chief Financial Officer and a Director of Vyome Holdings, Inc.

Was the transaction a market purchase or part of an internal reorganization?

The transaction was a merger-induced conversion under the Merger Agreement, not an open-market purchase or sale.

Does the Form 4 disclose any cash consideration received by the reporting person?

No cash consideration is disclosed; the Form 4 shows an in-kind conversion of subsidiary shares into parent-company common stock.